Evidence map›Paper›PMID 35778352›Full record

ArticleTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2022

COVID-19 convalescent plasma: current status, lessons from the past and future perspectives.

Tor Audun Hervig, Øystein Flesland, Lise Sofie Haug Nissen-Meyer

Abstract read
In one paragraph

Article in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tor Audun HervigLaboratory for Immunology and Transfusion Medicine, Haugesund Hospital, Norway. Electronic address: tor.hervig@helse-bergen.no.
Øystein FleslandNorwegian Directorate of Health, Oslo, Norway.
Lise Sofie Haug Nissen-MeyerDepartment of Immunology , Oslo University Hospital, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When the COVID-19 pandemic hit, blood transfusion services worldwide started collection of convalescent plasma as early as possible, as exemplified by the response in Norway. There were challenges related to donor selection, donor safety, testing for relevant antibodies and indications for and dosing of the convalescent plasma. As more knowledge became available, the product quality was more standardised. Multiple case reports, observational studies and some randomized studies were published during the pandemic, as well as laboratory studies reporting different approaches to antibody testing. The results were conflicting and the importance of convalescent plasma was disputed. Even though there has been strong international collaboration with involvement of many key organisations, we may better prepare for the next pandemic. An even stronger, more formalised collaboration between these organisations could provide more clear evidence of the importance of convalescent plasma, based on the principles of passive immunisation.

Indexed as

COVID-19PandemicsCOVID-19 SerotherapyHumansImmunization, PassiveSARS-CoV-2COVID-19 convalescent plasmaInternational collaborationRandomised clinical trials

Identifiers

PMID35778352
PMCPMC9188440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.